<p>A. Short exposure with DZNep for 4–8 h produced maximal cytotoxic effects. Cells were exposed with DZNep at 1 µM for varying time intervals followed by increasing concentrations of gemcitabine (0–0.1 µM). Significance between 0 and 4 h is indicated. B. Superior cytotoxicity and synergism between gemcitabine and DZNep were observed when cells were primed with DZNep, as opposed to cotreatment with gemcitabine. Representative growth inhibition curves are shown. Twenty-four hours after 3×10<sup>3</sup> cells/well were seeded in a 96-well plate, cells were exposed to gemcitabine and DZNep concentrations at a 1∶10 ratio either as a co-treatment for 72 h (C) or a primed treatment (with DZNep for 8 h followed by gemcitabine for 72 h) (P). Cellul...
<p>(A) The relative in vitro sensitivity of B16 parental, B16.Nuc, B16.Cyto, and B16.Sec tumor cells...
The marked clinical anticancer activity of the paclitaxel (PTX) and gemcitabine (GEM) combination ha...
Pancreatic ductal adenocarcinoma (PDAC) is characterized by overexpression of enhancer of Zeste homo...
<p>A. All cancerous cell lines excluding the normal HPDE are DZNep-responsive and reduced cellular v...
<p>A. Spatial distribution of DZNep and gemcitabine within NPs. Co-encapsulating double-emulsion for...
<p>DPEP1 overexpressing cells and control cells were analyzed for cellular sensitivity to gemcitabin...
<p>A. The chemical structures of DZNep and its two acyl prodrugs (Prodrug 1: C<sub>20</sub>H<sub>29<...
We evaluated the potential of an investigational histone methylation reversal agent, 3-deazaneplanoc...
<p>(A) Potentiation of gemcitabine-induced cell growth inhibition by pristimerin. Cells were grown i...
<div><p>We evaluated the potential of an investigational histone methylation reversal agent, 3-deaza...
Abstract Combination chemotherapy is commonly used to treat late stage cancer; however, treatment is...
<p>U2OS, MG63, A673, and HT1080 cells were treated with MK-1775 (500 nM) and gemcitabine (3 µM), eit...
Pancreatic ductal adenocarcinoma (PDAC) is characterized by overexpression of enhancer of Zeste homo...
Purpose: Since preclinical studies have shown more than additive cytotoxicity and DNA damage with th...
Synergistic cytotoxicity between cisplatin and the nucleoside analog gemcitabine was observed in a p...
<p>(A) The relative in vitro sensitivity of B16 parental, B16.Nuc, B16.Cyto, and B16.Sec tumor cells...
The marked clinical anticancer activity of the paclitaxel (PTX) and gemcitabine (GEM) combination ha...
Pancreatic ductal adenocarcinoma (PDAC) is characterized by overexpression of enhancer of Zeste homo...
<p>A. All cancerous cell lines excluding the normal HPDE are DZNep-responsive and reduced cellular v...
<p>A. Spatial distribution of DZNep and gemcitabine within NPs. Co-encapsulating double-emulsion for...
<p>DPEP1 overexpressing cells and control cells were analyzed for cellular sensitivity to gemcitabin...
<p>A. The chemical structures of DZNep and its two acyl prodrugs (Prodrug 1: C<sub>20</sub>H<sub>29<...
We evaluated the potential of an investigational histone methylation reversal agent, 3-deazaneplanoc...
<p>(A) Potentiation of gemcitabine-induced cell growth inhibition by pristimerin. Cells were grown i...
<div><p>We evaluated the potential of an investigational histone methylation reversal agent, 3-deaza...
Abstract Combination chemotherapy is commonly used to treat late stage cancer; however, treatment is...
<p>U2OS, MG63, A673, and HT1080 cells were treated with MK-1775 (500 nM) and gemcitabine (3 µM), eit...
Pancreatic ductal adenocarcinoma (PDAC) is characterized by overexpression of enhancer of Zeste homo...
Purpose: Since preclinical studies have shown more than additive cytotoxicity and DNA damage with th...
Synergistic cytotoxicity between cisplatin and the nucleoside analog gemcitabine was observed in a p...
<p>(A) The relative in vitro sensitivity of B16 parental, B16.Nuc, B16.Cyto, and B16.Sec tumor cells...
The marked clinical anticancer activity of the paclitaxel (PTX) and gemcitabine (GEM) combination ha...
Pancreatic ductal adenocarcinoma (PDAC) is characterized by overexpression of enhancer of Zeste homo...